06998 GENOR-B
- 1.300
- +0.030+2.36%
GENOR-B News
Jiahe Bio-B (06998) issued approximately 1.3796 million shares on May 27
Jiahe Bio-B (06998) announced that on May 27, 2024, the company selected participants based on...
嘉和生物-B：2023年度報告
Jiahe Bio-B issued 4.442,400 shares due to the exercise of share options
Jiahe Bio-B (06998) announced that on April 10, 2024, the company issued 4.442,400 shares due to director Guo Feng exercising share options under the pre-initial public offering share option plan.
As a result of the exercise of share options, Jiahe Bio-B (06998) issued 4.442,400 shares
According to Zhitong Finance App News, Jiahe Bio-B (06998) announced that on April 10, 2024, the company issued 4.442,400 shares due to director Guo Feng exercising share options under the pre-initial public offering share option plan.
Jiahe Bio-B (06998) issued 12,000 shares to exercise share options under the pre-initial public offering share option plan on April 2
Jiahe Biological-B (06998) issued an announcement on April 2, 2024 due to the initial disclosure of eligible employees...
Jiahe Bio-B (06998) announced 2023 results. Losses attributable to owners of about 674 million yuan narrowed 7.65% year-on-year
Jiahe Bio-B (06998) announced its 2023 results. The total revenue was zero, and the 2022 revenue was about 159...
GENOR-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 AND PROPOSED ADOPTION OF THE EIGHTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
China's Drug Regulator Accepts Genor Biopharma's New Breast Cancer Drug Application; Shares Up 7%
Genor Biopharma Holdings (HKG:6998) said China's National Medical Products Administration officially accepted its new drug application for GB491 combined with Letrozole for advanced breast cancer trea
Jiahe Bio-B (06998.HK): China National Drug Administration accepted the marketing license application for a new drug of lerocilide hydrochloride tablets (GB491, Lerociclib)
Gelonghui, March 13, 丨 Jiahe Bio-B (06998.HK) announced that on March 13, 2024, the China National Drug Administration (“NMPA”) has officially accepted a new drug marketing license application (“NDA”) for patients with advanced breast cancer (GB491, Lerociclib) combined with letrozole to treat hormone receptor (HR) positive and negative human epidermal growth factor receptor 2 (HER2-) without prior systemic anti-tumor treatment. Previously, lerocilide hydrochloride tablets (GB491, Lerocicli
Jiahe Bio-B (06998.HK) will hold a board meeting on March 27 to approve the full year results
Gelonghui March 13 | Jiahe Bio-B (06998.HK) issued an announcement. The board of directors of the company will hold a board meeting on March 27, 2024 to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
Jiahe Bio-B (06998) issues 285,000 shares due to the ownership of restricted share units
According to Zhitong Finance App News, Jiahe Bio-B (06998) announced that on January 25, 2024, the company will issue 285,000 shares due to selected participants belonging to restricted share units in accordance with the 2021 Restricted Share Unit Plan adopted on June 3, 2021. On the same day, the company issued 8,500 shares at an issue price of HK$0.00155 per share as a result of eligible employees exercising share options under the pre-initial public offering share option scheme.
Jiahe Biotech B (06998) issued 52,500 shares due to ownership of restricted stock units
Jiahe Biotechnology-B (06998) announced on December 22, 2023, since participants were selected based on 2021...
Jiahe Biotech B issues 4,500 shares due to ownership of restricted share units
Jiahe Biotech B (06998) announced that on December 7, 2023, the company issued 4,500 shares as selected participants to belong to restricted share units in accordance with the 2021 restricted share unit plan adopted on June 3, 2021.
Jiahe Biotech B issued 19,000 shares due to the adoption of the 2021 restricted share unit plan
Jiahe Biotechnology-B (06998) issued an announcement on November 2, 2023, to issue 19,000 shares due to selected participants belonging to restricted share units in accordance with the 2021 restricted share unit plan adopted on June 3, 2021, and 250 shares due to eligible employees exercising share options under the pre-IPO share option plan.
Jiahe Biotech B (06998) issued 19,000 shares due to the adoption of the 2021 restricted share unit plan
Jiahe Biotechnology-B (06998) issued an announcement on November 2, 2023, due to the selection of participants based on 202...
Jiahe Bio-B issued a total of 597,200 shares on October 10
Jiahe Bio-B (06998) announced that on October 10, 2023, 568,200 shares were issued due to the exercise of consideration shares under the ABT subscription and share purchase agreement; 29,000 shares were issued because eligible employees exercised share options under the pre-initial public offering share option plan.
Jiahe Bio-B (06998) issued a total of 597,200 shares on October 10
Jiahe Bio-B (06998) announced that on October 10, 2023, due to the subscription and purchase according to ABT...
GENOR-B: 2023 Interim Report
Jiahe Biotech B was assigned and issued 71,500 shares due to restricted stock units
Jiahe Bio-B (06998) announced that on September 25, 2023, the company issued 71,500 shares due to selected participants belonging to restricted share units in accordance with the 2021 restricted share unit plan adopted on June 3, 2021.
Jiahe Biotech B was assigned and issued 25,000 shares due to restricted stock units
Jiahe Bio-B (06998) announced that on September 6, 2023, it will issue 110 shares due to eligible employees exercising share options under the pre-IPO share option plan. On September 7, 2023, 25,000 shares were issued due to selected participants belonging to restricted share units under the 2021 Restricted Share Unit Plan adopted on June 3, 2021.
Analysis
Price Target
No Data
